menu
    • menu
    [{"orgOrder":0,"company":"Immunoforge","sponsor":"PhaseBio Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"PF1801","moa":"GLP-1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immunoforge","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Immunoforge \/ PhaseBio","highestDevelopmentStatusID":"6","companyTruncated":"Immunoforge \/ PhaseBio"},{"orgOrder":0,"company":"Immunoforge","sponsor":"Duke University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Immunoforge","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunoforge \/ Duke University","highestDevelopmentStatusID":"2","companyTruncated":"Immunoforge \/ Duke University"},{"orgOrder":0,"company":"Immunoforge","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Froniglutide","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Immunoforge","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunoforge \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunoforge \/ Not Applicable"},{"orgOrder":0,"company":"Immunoforge","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Immunoforge","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Immunoforge \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunoforge \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Immunoforge

    Menu

    Immunoforge

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Immunoforge

                            South Korea arrow
                            Biotech Digital Meet
                            Not Confirmed

                            Immunoforge

                            South Korea arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pemziviptadil

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ImmunoForge Receives IND Approval for Pemziviptadil in DMD Cardiomyopathy

                            Details : PF1804 (pemziviptadil) is a vasoactive intestinal peptide that selectively acts on the vasoactive intestinal peptide receptor 2 (VPAC2), it is being investigated for treating DMD cardiomyopathy.

                            Product Name : PF1804

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            January 14, 2025

                            Lead Product(s) : Pemziviptadil

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Immunoforge

                            South Korea arrow
                            Biotech Digital Meet
                            Not Confirmed

                            Immunoforge

                            South Korea arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Froniglutide

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ImmunoForge Doses First Patient in Phase 2 Clinical Trial of Froniglutide for Dermatomyositis/Polymyositis

                            Details : PF1801 (froniglutide) is a weekly GLP-1 receptor agonist biotherapeutic designed to increase muscle mass and strength by directly acting on muscle cells through targeting GLP-1 receptors that are overexpressed in the muscles of patients with DM/PM.

                            Product Name : PF1801

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            October 17, 2023

                            Lead Product(s) : Froniglutide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Immunoforge

                            South Korea arrow
                            Biotech Digital Meet
                            Not Confirmed

                            Immunoforge

                            South Korea arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Duke University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ImmunoForge Expands Drug Development Licensing Agreement with Duke University

                            Details : Under the agreement, Duke University will have the right to develop new anticancer drugs with the ELP platform technology and ImmunoForge will retain the right to develop new products in all therapeutic areas other than anticancer drugs.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 18, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Duke University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Immunoforge

                            South Korea arrow
                            Biotech Digital Meet
                            Not Confirmed

                            Immunoforge

                            South Korea arrow
                            Biotech Digital Meet
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PF1801

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : PhaseBio Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immunoforge's 'PF1801' Is Designated as Orphan Drug by FDA

                            Details : Immunoforge is developing agents for rare muscle related diseases, such as Duchenne muscular dystrophy, polymyositis, and inclusion body myositis, based on its patent with PF1801 from PhaseBio, which has completed phase 2 clinical trials.

                            Product Name : PF1801

                            Product Type : Undisclosed

                            Upfront Cash : Not Applicable

                            January 28, 2021

                            Lead Product(s) : PF1801

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : PhaseBio Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth